Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter

Neuron. 2023 May 17;111(10):1626-1636.e6. doi: 10.1016/j.neuron.2023.02.017. Epub 2023 Mar 13.

Abstract

Lasker's award-winning drug propofol is widely used in general anesthesia. The recreational use of propofol is reported to produce a well-rested feeling and euphoric state; yet, the neural mechanisms underlying such pleasant effects remain unelucidated. Here, we report that propofol actively and directly binds to the dopamine transporter (DAT), but not the serotonin transporter (SERT), which contributes to the rapid relief of anhedonia. Then, we predict the binding mode of propofol by molecular docking and mutation of critical binding residues on the DAT. Fiber photometry recording on awake freely moving mice and [18F] FP-CIT-PET scanning further establishes that propofol administration evokes rapid and lasting dopamine accumulation in nucleus accumbens (NAc). The enhanced dopaminergic tone drives biased activation of dopamine-receptor-1-expressing medium spiny neurons (D1-MSNs) in NAc and reverses anhedonia in chronically stressed animals. Collectively, these findings suggest the therapeutic potential of propofol against anhedonia, which warrants future clinical investigations.

Keywords: D1-MSNs; anti-anhedonia; dopamine transporter; nucleus accumbens; propofol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anhedonia
  • Animals
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Dopamine* / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • Nucleus Accumbens / physiology
  • Propofol* / metabolism
  • Propofol* / pharmacology
  • Receptors, Dopamine D1 / metabolism

Substances

  • Dopamine
  • Propofol
  • Dopamine Plasma Membrane Transport Proteins
  • Receptors, Dopamine D1